PI3Kδ inhibition hits a sensitive spot in B cell malignancies

Cancer Cell. 2014 Mar 17;25(3):269-71. doi: 10.1016/j.ccr.2014.02.012.

Abstract

A PI3Kδ-selective inhibitor shows impressive clinical activity in chronic lymphocytic leukemia and indolent B cell non-Hodgkin's lymphomas. In these malignancies, the PI3K pathway is not mutationally activated as in many other cancers, but it is important for mediating supportive cues from the cancer microenvironment and the B cell antigen receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • B-Lymphocytes / drug effects
  • Cell Differentiation
  • Cell Movement
  • Cell Proliferation
  • Cell Survival
  • Class I Phosphatidylinositol 3-Kinases
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Phosphoinositide-3 Kinase Inhibitors*
  • Purines / therapeutic use*
  • Quinazolinones / therapeutic use*
  • Receptors, Antigen, B-Cell / metabolism
  • Rituximab
  • Signal Transduction / drug effects

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • Purines
  • Quinazolinones
  • Receptors, Antigen, B-Cell
  • Rituximab
  • Class I Phosphatidylinositol 3-Kinases
  • PIK3CD protein, human
  • idelalisib